APA (7th ed.) Citation

M, F., AP, K., S, R., J, v. T., C, Z., M, G., . . . B, E. (2024). First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 25(6), 744. https://doi.org/10.1016/S1470-2045(24)00196-7

Chicago Style (17th ed.) Citation

M, Fürstenau, et al. "First-line Venetoclax Combinations Versus Chemoimmunotherapy in Fit Patients with Chronic Lymphocytic Leukaemia (GAIA/CLL13): 4-year Follow-up from a Multicentre, Open-label, Randomised, Phase 3 Trial." The Lancet. Oncology 25, no. 6 (2024): 744. https://doi.org/10.1016/S1470-2045(24)00196-7.

MLA (9th ed.) Citation

M, Fürstenau, et al. "First-line Venetoclax Combinations Versus Chemoimmunotherapy in Fit Patients with Chronic Lymphocytic Leukaemia (GAIA/CLL13): 4-year Follow-up from a Multicentre, Open-label, Randomised, Phase 3 Trial." The Lancet. Oncology, vol. 25, no. 6, 2024, p. 744, https://doi.org/10.1016/S1470-2045(24)00196-7.